COOL AMI EU pilot trial: a multicentre, prospective, randomised controlled trial to assess cooling as an adjunctive therapy to percutaneous intervention in patients with acute myocardial infarction

Noc, Marko and Erlinge, David and Neskovic, Aleksandar and Kafedzic, Srdjan and Merkely, Béla and Zima, Endre and Fister, Misa and Petrović, Milovan and Čanković, Milenko and Veress, Gábor and Laanmets, Peep and Pern, Teele and Vukcevic, Vladan and Dedovic, Vladimir and Średniawa, Beata and Świątkowski, Andrzej and Keeble, Thomas R. and Davies, John and Warenits, Alexandra-Maria and Olivecrona, Göran and Peruga, Jan and Ciszewski, Michal and Horvath, Ivan and Edes, Istvan and Nagy, Gergely and Aradi, Daniel and Holzer, Michael (2017) COOL AMI EU pilot trial: a multicentre, prospective, randomised controlled trial to assess cooling as an adjunctive therapy to percutaneous intervention in patients with acute myocardial infarction. EuroIntervention, 13 (5). e531-e539. ISSN 1969-6213

[img] Text (Correspondence - not final output)
Other
Restricted to Repository staff only

Download (93kB)
Official URL: https://doi.org/10.4244/EIJ-D-17-00279

Abstract

Aims: We aimed to investigate the rapid induction of therapeutic hypothermia using the ZOLL Proteus Intravascular Temperature Management System in patients with anterior ST-elevation myocardial infarction (STEMI) without cardiac arrest. Methods and results: A total of 50 patients were randomised; 22 patients (88%; 95% confidence interval [CI]: 69-97%) in the hypothermia group and 23 patients (92%; 95% CI: 74-99) in the control group completed cardiac magnetic resonance imaging at four to six days and 30-day follow-up. Intravascular temperature at coronary guidewire crossing after 20.5 minutes of endovascular cooling decreased to 33.6°C (range 31.9-35.5°C). There was a 17-minute (95% CI: 4.6-29.8 min) cooling-related delay to reperfusion. In “per protocol” analysis, median infarct size/left ventricular mass was 16.7% in the hypothermia group versus 23.8% in the control group (absolute reduction 7.1%, relative reduction 30%; p=0.31) and median left ventricular ejection fraction (LVEF) was 42% in the hypothermia group and 40% in the control group (absolute reduction 2.4%, relative reduction 6%; p=0.36). Except for self-terminating paroxysmal atrial fibrillation (32% versus 8%; p=0.074), there was no excess of adverse events in the hypothermia group. Conclusions: We rapidly and safely cooled patients with anterior STEMI to 33.6°C at the time of coronary guidewire crossing. This is ≥1.1°C lower than in previous cooling studies. Except for self-terminating atrial fibrillation, there was no excess of adverse events and no clinically important cooling-related delay to reperfusion. A statistically non-significant numerical 7.1% absolute and 30% relative reduction in infarct size warrants a pivotal trial powered for efficacy. ClinicalTrials.gov Identifier: NCT02509832

Item Type: Journal Article
Faculty: Faculty of Medical Science
Depositing User: Ian Walker
Date Deposited: 02 Feb 2018 15:10
Last Modified: 02 Feb 2018 15:18
URI: http://arro.anglia.ac.uk/id/eprint/702700

Actions (login required)

Edit Item Edit Item